EQL Pharma AB preliminarily announces very strong outcome for the third quarter and reports continued strongly increasing order intake
EQL Pharma AB (“EQL” or “the Company”) publishes in advance an update regarding the third quarter before the planned quarterly report on February 16, 2022 and announces that order intake during the ongoing fourth quarter continues to increase sharply.The preliminary summary for the third quarter (period October - December 2021) shows that net sales amounted to approximately SEK 117 million (SEK 29.61 million) and that EBIT amounted to approximately SEK 18 million (SEK 2.35 million). The increase in sales is explained by a very strong demand for the Company's self-tests for Covid-19, which